RU2432364C2 - ПОЛИКЛОНАЛЬНОЕ АНТИТЕЛО ПРОТИВ Nogo, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И ПРИМЕНЕНИЕ АНТИТЕЛА ДЛЯ ИЗГОТОВЛЕНИЯ ЛЕКАРСТВЕННОГО СРЕДСТВА - Google Patents

ПОЛИКЛОНАЛЬНОЕ АНТИТЕЛО ПРОТИВ Nogo, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И ПРИМЕНЕНИЕ АНТИТЕЛА ДЛЯ ИЗГОТОВЛЕНИЯ ЛЕКАРСТВЕННОГО СРЕДСТВА Download PDF

Info

Publication number
RU2432364C2
RU2432364C2 RU2009103533/10A RU2009103533A RU2432364C2 RU 2432364 C2 RU2432364 C2 RU 2432364C2 RU 2009103533/10 A RU2009103533/10 A RU 2009103533/10A RU 2009103533 A RU2009103533 A RU 2009103533A RU 2432364 C2 RU2432364 C2 RU 2432364C2
Authority
RU
Russia
Prior art keywords
antibody
polyclonal
fragment
pharmaceutical composition
application
Prior art date
Application number
RU2009103533/10A
Other languages
English (en)
Other versions
RU2009103533A (ru
Inventor
Мартин Э. ШВАБ (CH)
Мартин Э. ШВАБ
Майо С. ЧЕН (CH)
Майо С. ЧЕН
Original Assignee
Юниверсити Оф Цюрих
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22316666&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2432364(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Юниверсити Оф Цюрих filed Critical Юниверсити Оф Цюрих
Publication of RU2009103533A publication Critical patent/RU2009103533A/ru
Application granted granted Critical
Publication of RU2432364C2 publication Critical patent/RU2432364C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)

Abstract

Изобретение относится к биотехнологии и представляет собой поликлональное антитело против Nogo. Также представлены фармацевтическая композиция и применение антитела для приготовления лекарственного средства. Изобретение может эффективно использоваться для лечения расстройств центральной нервной системы. 3 н. и 3 з.п. ф-лы, 79 ил., 2 табл.

Description

Текст описания приведен в факсимильном виде.
Figure 00000001
Figure 00000002
Figure 00000003
Figure 00000004
Figure 00000005
Figure 00000006
Figure 00000007
Figure 00000008
Figure 00000009
Figure 00000010
Figure 00000011
Figure 00000012
Figure 00000013
Figure 00000014
Figure 00000015
Figure 00000016
Figure 00000017
Figure 00000018
Figure 00000019
Figure 00000020
Figure 00000021
Figure 00000022
Figure 00000023
Figure 00000024
Figure 00000025
Figure 00000026
Figure 00000027
Figure 00000028
Figure 00000029
Figure 00000030
Figure 00000031
Figure 00000032
Figure 00000033
Figure 00000034
Figure 00000035
Figure 00000036
Figure 00000037
Figure 00000038
Figure 00000039
Figure 00000040
Figure 00000041
Figure 00000042
Figure 00000043
Figure 00000044
Figure 00000045
Figure 00000046
Figure 00000047
Figure 00000048
Figure 00000049
Figure 00000050
Figure 00000051
Figure 00000052
Figure 00000053
Figure 00000054
Figure 00000055
Figure 00000056
Figure 00000057
Figure 00000058
Figure 00000059
Figure 00000060
Figure 00000061
Figure 00000062
Figure 00000063
Figure 00000064
Figure 00000065
Figure 00000066
Figure 00000067
Figure 00000068
Figure 00000069
Figure 00000070
Figure 00000071
Figure 00000072
Figure 00000073
Figure 00000074
Figure 00000075
Figure 00000076
Figure 00000077
Figure 00000078
Figure 00000079
Figure 00000080
Figure 00000081
Figure 00000082
Figure 00000083
Figure 00000084
Figure 00000085
Figure 00000086
Figure 00000087
Figure 00000088
Figure 00000089
Figure 00000090
Figure 00000091
Figure 00000092
Figure 00000093
Figure 00000094
Figure 00000095
Figure 00000096
Figure 00000097
Figure 00000098
Figure 00000099
Figure 00000100
Figure 00000101
Figure 00000102
Figure 00000103
Figure 00000104
Figure 00000105
Figure 00000106
Figure 00000107
Figure 00000108
Figure 00000109
Figure 00000110
Figure 00000111
Figure 00000112
Figure 00000113
Figure 00000114
Figure 00000115
Figure 00000116
Figure 00000117
Figure 00000118
Figure 00000119
Figure 00000120
Figure 00000121
Figure 00000122
Figure 00000123
Figure 00000124
Figure 00000125
Figure 00000126
Figure 00000127
Figure 00000128
Figure 00000129
Figure 00000130
Figure 00000131
Figure 00000132
Figure 00000133
Figure 00000134
Figure 00000135
Figure 00000136
Figure 00000137
Figure 00000138
Figure 00000139
Figure 00000140
Figure 00000141
Figure 00000142
Figure 00000143
Figure 00000144
Figure 00000145
Figure 00000146
Figure 00000147
Figure 00000148
Figure 00000149
Figure 00000150
Figure 00000151
Figure 00000152
Figure 00000153
Figure 00000154
Figure 00000155
Figure 00000156
Figure 00000157
Figure 00000158
Figure 00000159
Figure 00000160
Figure 00000161
Figure 00000162
Figure 00000163
Figure 00000164
Figure 00000165
Figure 00000166
Figure 00000167

Claims (6)

1. Поликлональное антитело против Nogo или его фрагмент, которое получено способом, включающим иммунизацию животного полипептидом с аминокислотной последовательностью SEQ ID NO: 29 и выделение поликлонального антитела из животного.
2. Антитело по п.1, где указанный полипептид представляет собой синтетический пептид.
3. Антитело по п.1, где указанное антитело представляет собой человеческое антитело.
4. Антитело по п.1 или 3, где фрагмент антитела выбран из группы, состоящей из фрагмента Fab, фрагмента Fab', фрагмента Fv или фрагмента Р(ab')2 антитела.
5. Фармацевтическая композиция для индуцирования регенерации или ветвления нейронов, содержащая эффективное количество антитела по любому из пп.1-4 и фармацевтически приемлемый носитель.
6. Применение антитела по любому из пп.1-4 для изготовления лекарственного средства для индуцирования регенерации или ветвления нейронов.
RU2009103533/10A 1998-11-06 2009-02-03 ПОЛИКЛОНАЛЬНОЕ АНТИТЕЛО ПРОТИВ Nogo, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И ПРИМЕНЕНИЕ АНТИТЕЛА ДЛЯ ИЗГОТОВЛЕНИЯ ЛЕКАРСТВЕННОГО СРЕДСТВА RU2432364C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10744698P 1998-11-06 1998-11-06
US60/107,446 1998-11-06

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2004103555/13A Division RU2358982C2 (ru) 1998-11-06 2004-02-06 Способы получения поликлональных антител, антисыворотка, содержащая поликлональные антитела, и способы иммунизации

Publications (2)

Publication Number Publication Date
RU2009103533A RU2009103533A (ru) 2010-11-10
RU2432364C2 true RU2432364C2 (ru) 2011-10-27

Family

ID=22316666

Family Applications (3)

Application Number Title Priority Date Filing Date
RU2001115705/13A RU2304585C2 (ru) 1998-11-06 1999-11-05 Очищенный иммуногенный белок, его фрагменты и производные
RU2004103555/13A RU2358982C2 (ru) 1998-11-06 2004-02-06 Способы получения поликлональных антител, антисыворотка, содержащая поликлональные антитела, и способы иммунизации
RU2009103533/10A RU2432364C2 (ru) 1998-11-06 2009-02-03 ПОЛИКЛОНАЛЬНОЕ АНТИТЕЛО ПРОТИВ Nogo, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И ПРИМЕНЕНИЕ АНТИТЕЛА ДЛЯ ИЗГОТОВЛЕНИЯ ЛЕКАРСТВЕННОГО СРЕДСТВА

Family Applications Before (2)

Application Number Title Priority Date Filing Date
RU2001115705/13A RU2304585C2 (ru) 1998-11-06 1999-11-05 Очищенный иммуногенный белок, его фрагменты и производные
RU2004103555/13A RU2358982C2 (ru) 1998-11-06 2004-02-06 Способы получения поликлональных антител, антисыворотка, содержащая поликлональные антитела, и способы иммунизации

Country Status (27)

Country Link
US (4) US7781188B1 (ru)
EP (3) EP2093294B1 (ru)
JP (2) JP2003531566A (ru)
KR (1) KR100728405B1 (ru)
CN (3) CN1354755B (ru)
AT (1) ATE435232T1 (ru)
AU (1) AU774367C (ru)
BR (1) BR9915137A (ru)
CA (1) CA2350395C (ru)
CY (1) CY1110679T1 (ru)
CZ (1) CZ304224B6 (ru)
DE (1) DE69941059D1 (ru)
DK (1) DK1124846T3 (ru)
ES (2) ES2329635T3 (ru)
HK (1) HK1038027A1 (ru)
HU (1) HUP0301829A3 (ru)
IL (3) IL142989A0 (ru)
MX (1) MXPA01004598A (ru)
NO (1) NO332460B1 (ru)
NZ (1) NZ511683A (ru)
PL (1) PL204293B1 (ru)
PT (1) PT1124846E (ru)
RU (3) RU2304585C2 (ru)
SK (1) SK287323B6 (ru)
TR (1) TR200700740T2 (ru)
WO (1) WO2000031235A2 (ru)
ZA (1) ZA200103714B (ru)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020072493A1 (en) 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
ATE483021T1 (de) * 1998-07-22 2010-10-15 Smithkline Beecham Ltd Protein, das mit einem neuroendokrinspezifischen protein änhelt, und dafür kodierende cdns
CZ304224B6 (cs) 1998-11-06 2014-01-15 Schwab Monoklonální protilátka
AU4216200A (en) * 1999-04-08 2000-10-23 Chiron Corporation Novel protein associated with cell stress response
US7186530B1 (en) 2000-04-07 2007-03-06 Chiron Corporation Protein associated with cell stress response
ATE466882T1 (de) * 2000-01-12 2010-05-15 Univ Yale Nogo rezeptor-vermittelte blockade des axonalen wachstums
US7119165B2 (en) 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
US7049395B2 (en) 2000-05-02 2006-05-23 Yale University Anti-inflammatory compounds and uses thereof
EP1325130B1 (en) 2000-10-06 2010-02-24 Yale University Nogo receptor homologs
GB0101313D0 (en) * 2001-01-18 2001-02-28 Glaxo Group Ltd Assay
GB0101312D0 (en) * 2001-01-18 2001-02-28 Glaxo Group Ltd Assay
AR040778A1 (es) 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
AU2002368307A1 (en) * 2002-10-31 2004-05-25 Pieris Proteolab Ag Soluble truncated polypeptides of the nogo-a protein
GB0306309D0 (en) 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment
PT2248899E (pt) 2003-03-19 2015-09-23 Biogen Ma Inc Proteína de ligação do receptor nogo
AU2004303585B2 (en) * 2003-12-22 2010-12-23 Glaxo Group Limited NOGO-a neutralising immunoglobulins for treatment of neurological diseases
ES2395094T3 (es) 2004-06-24 2013-02-08 Biogen Idec Ma Inc. Tratamiento de afecciones que implican la desmielinización
KR100659820B1 (ko) 2004-11-17 2006-12-19 삼성에스디아이 주식회사 리튬 이온 이차 전지
US20090137484A1 (en) * 2004-12-01 2009-05-28 National University Of Singapore Neuronal Network-Interacting Peptide
US7893032B2 (en) 2005-07-07 2011-02-22 Yale University NgR variants and compositions thereof for suppressing axonal growth inhibition
EP2238986A3 (en) 2005-07-08 2010-11-03 Biogen Idec MA Inc. Sp35 antibodies and uses thereof
WO2007014382A1 (en) * 2005-07-28 2007-02-01 Wyeth Compositions and methods of mutant nogo-66 domain proteins
EP2299267A3 (en) 2005-11-16 2011-05-04 Novartis AG Biomarkers for anti-NogoA antibody treatment in spinal cord injury
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
CA2653456A1 (en) * 2006-05-24 2007-11-29 Richard Daneman Permeability of blood-brain barrier
CN101015683B (zh) * 2007-01-18 2010-07-21 复旦大学 人rtn4b蛋白在制备创伤愈合药物中的应用
DK2207808T3 (da) * 2007-11-02 2013-08-05 Novartis Ag Forbedrede Nogo-A-bindingsmolekyler samt deres farmaceutiske anvendelse
CN101874207A (zh) * 2007-11-22 2010-10-27 西福根有限公司 用于表征重组多克隆蛋白质的方法
WO2010005570A2 (en) 2008-07-09 2010-01-14 Biogen Idec Ma Inc. Compositions comprising antibodies to lingo or fragments thereof
WO2010141421A1 (en) * 2009-06-02 2010-12-09 The Board Of Regents Of The University Of Texas System Identification of small molecules recognized by antibodies in subjects with neurodegenerative diseases
WO2012004773A1 (en) 2010-07-09 2012-01-12 Universite De Geneve New uses of nogo-a inhibitors and related methods
RU2478646C1 (ru) * 2011-11-28 2013-04-10 Федеральное государственное бюджетное учреждение науки Институт молекулярной биологии им.В.А.Энгельгардта Российской академии наук (ИМБ РАН) Способ получения высокоаффинных поликлональных антител
EA030716B1 (ru) 2012-05-14 2018-09-28 Байоджен Ма Инк. Антагонисты lingo-2 для лечения заболеваний, в которых участвуют двигательные нейроны
MX366880B (es) * 2013-08-08 2019-07-29 Global Bio Therapeutics Inc Dispositivo de inyección para procedimientos mínimamente invasivos y usos del mismo.
KR101685109B1 (ko) * 2014-12-22 2016-12-09 경북대학교 산학협력단 근육 분화, 재생, 또는 질환 상태와 관련된 노고-에이의 용도
US10435467B2 (en) 2015-01-08 2019-10-08 Biogen Ma Inc. LINGO-1 antagonists and uses for treatment of demyelinating disorders
WO2016120290A1 (en) * 2015-01-27 2016-08-04 Universität Zürich Agonists of the nogo-a s1pr pathway for the treatment of glioblastoma

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) * 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
CA1173823A (en) 1980-08-26 1984-09-04 Leonard M. Hjelmeland Nondenaturing zwitterionic detergent for membrane biochemistry
EP0155433A1 (en) 1984-03-23 1985-09-25 Adriano Fontana Immunosuppressant factor
CA1341401C (en) 1984-03-23 2002-11-26 Adriano Fontana Immunosuppressant factor derived from human glioblastoma cells
EP0233838A3 (en) 1986-02-04 1990-01-31 Incyte Pharmaceuticals, Inc. Neurite-promoting factor and process for the manufacture thereof
WO1989012690A1 (en) 1988-06-13 1989-12-28 American Biogentic Sciences, Inc. Method for the production of monoclonal antibodies utilizing a germfree animal
ATE124726T1 (de) 1988-11-04 1995-07-15 Zuerich Erziehungsdirektion Wachstumsregelfaktoren für neuriten.
CA1341050C (en) * 1988-11-04 2000-07-11 Martin E. Schwab Neurite growth regulatory factors
US5250414A (en) 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
AU2152092A (en) 1991-06-24 1993-01-25 Erziehungsdirektion Of The Canton Zurich Neurite growth regulatory factors
US5858708A (en) * 1996-08-12 1999-01-12 Bandman; Olga Polynucleotides encoding two novel human neuroendocrine-specific proteins
CA2269755A1 (en) * 1996-10-25 1998-04-30 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
JP2002511231A (ja) * 1997-12-30 2002-04-16 カイロン コーポレイション 骨髄分泌タンパク質およびポリヌクレオチド
US6607879B1 (en) * 1998-02-09 2003-08-19 Incyte Corporation Compositions for the detection of blood cell and immunological response gene expression
US20020072493A1 (en) * 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
ATE483021T1 (de) 1998-07-22 2010-10-15 Smithkline Beecham Ltd Protein, das mit einem neuroendokrinspezifischen protein änhelt, und dafür kodierende cdns
JP2002537757A (ja) * 1998-08-24 2002-11-12 アルファジーン・インコーポレイテッド 分泌タンパク質及びそれらをコードするポリヌクレオチド
CZ304224B6 (cs) 1998-11-06 2014-01-15 Schwab Monoklonální protilátka
WO2001036631A1 (en) * 1999-11-15 2001-05-25 Smithkline Beecham P.L.C. Human nogo-c polynucleotide and polypeptide and their uses
US20030134301A1 (en) * 2001-07-27 2003-07-17 Brooksbank Robert Alan Identification and use of molecules implicated in pain

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CADELLI DS, et al. "Myelin-associated inhibitors of neurite outgrowth and their role in CNS regeneration". Ann NY Acad Sci. 1991; 633:234-240. ГАЛАКТИОНОВ В.Г. Иммунология. - М.: МГУ, 1998, с.52-79. *

Also Published As

Publication number Publication date
MXPA01004598A (es) 2002-04-24
NZ511683A (en) 2004-06-25
ATE435232T1 (de) 2009-07-15
CN1721444A (zh) 2006-01-18
ZA200103714B (en) 2004-06-25
IL142989A0 (en) 2002-04-21
AU774367C (en) 2005-04-21
WO2000031235A2 (en) 2000-06-02
SK287323B6 (sk) 2010-07-07
AU1469200A (en) 2000-06-13
CZ304224B6 (cs) 2014-01-15
IL198027A (en) 2011-10-31
WO2000031235A3 (en) 2000-11-09
RU2001115705A (ru) 2004-03-10
TR200700740T2 (tr) 2007-04-24
EP2093294B1 (en) 2014-10-29
EP1124846A4 (en) 2002-06-12
RU2304585C2 (ru) 2007-08-20
HUP0301829A3 (en) 2009-03-30
US20050260616A1 (en) 2005-11-24
NO332460B1 (no) 2012-09-24
PT1124846E (pt) 2009-10-08
EP1124846A2 (en) 2001-08-22
CA2350395C (en) 2014-07-08
HK1038027A1 (en) 2002-03-01
RU2358982C2 (ru) 2009-06-20
KR20020003353A (ko) 2002-01-12
JP2003531566A (ja) 2003-10-28
DE69941059D1 (de) 2009-08-13
EP2333064A1 (en) 2011-06-15
EP2093294A1 (en) 2009-08-26
JP2012213406A (ja) 2012-11-08
RU2009103533A (ru) 2010-11-10
NO20012223D0 (no) 2001-05-04
US20110086034A1 (en) 2011-04-14
DK1124846T3 (da) 2009-10-26
SK6222001A3 (en) 2001-12-03
IL142989A (en) 2010-12-30
US7781188B1 (en) 2010-08-24
PL362990A1 (en) 2004-11-15
BR9915137A (pt) 2004-06-08
KR100728405B1 (ko) 2007-06-13
RU2004103555A (ru) 2005-07-20
CN101684155A (zh) 2010-03-31
CN1354755B (zh) 2010-06-02
PL204293B1 (pl) 2009-12-31
AU774367B2 (en) 2004-06-24
CN1354755A (zh) 2002-06-19
ES2529196T3 (es) 2015-02-17
CA2350395A1 (en) 2000-06-02
NO20012223L (no) 2001-07-02
CY1110679T1 (el) 2015-06-10
HUP0301829A2 (hu) 2003-08-28
ES2329635T3 (es) 2009-11-27
CZ20011608A3 (cs) 2001-10-17
US20090162367A1 (en) 2009-06-25
EP1124846B1 (en) 2009-07-01
US7425334B2 (en) 2008-09-16

Similar Documents

Publication Publication Date Title
RU2432364C2 (ru) ПОЛИКЛОНАЛЬНОЕ АНТИТЕЛО ПРОТИВ Nogo, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И ПРИМЕНЕНИЕ АНТИТЕЛА ДЛЯ ИЗГОТОВЛЕНИЯ ЛЕКАРСТВЕННОГО СРЕДСТВА
RU2220980C2 (ru) Химерное антитело, которое связывается с cd40 человека (варианты), молекула нуклеиновой кислоты (варианты), вектор экспрессии (варианты), гуманизированное антитело (варианты), фармацевтическая композиция для лечения заболевания, опосредованного т-клетками (варианты), способ лечения больного от заболевания, опосредованного т-клетками (варианты)
RU2421464C2 (ru) Человеческие антитела к il-13 и их терапевтическое применение
HUP9802401A2 (hu) Az emberi gp39-protein különböző epitópjaira specifikus monoklonális antitestek, valamint eljárások az ilyen antitestek diagnosztikai és terápiás alkalmazására
AU679909B2 (en) Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon
RU2317998C2 (ru) Антитела человека, обладающие активностью связывания c mn и нейтрализации клеточной адгезии
JP2013126993A (ja) 治療ワクチン
EP0117114A2 (en) Monoclonal antibody
ATE330631T1 (de) Antikörperfragmente zur lokalen behandlung von augenerkrankungen
CA2111189A1 (en) Oral treatment of helicobacter infection
DE68925226D1 (de) Monoklonale Antikörper
EP0710121A1 (en) Method for treating multiple sclerosis
CA2459348A1 (en) Antibodies to non-functional p2x7receptor, diagnosis and treatment of cancers and other conditions
EP0350690A3 (de) Neutralisation der in vitro- und in vivo-toxischen Eigenschaften von TNF-alfa durch monoklonale Antikörper und die davon abgeleiteten Fragmente
CA2252438A1 (en) Histidine-tagged intimin and methods of using intimin to stimulate an immune response and as an antigen carrier with targeting capability
JP2852705B2 (ja) 自己免疫疾患の治療
RU2001130068A (ru) Антиидиотипические антитела к антителам, которые ингибируют связывание иммуноглобулина с его высокоаффинным рецептором
DE69737323D1 (de) Adhesin aus heliobacter pylori, welches an blutgruppenantigene bindet
Dalakas et al. Thymosin β4 is a shared antigen between lymphoid cells and oligodendrocytes of normal human brain
JPH01501793A (ja) 透明帯に対する免疫化による避妊のための方法
US5723582A (en) Antigen-specific human glycosylation inhibiting factor
EP0345260A1 (en) Method of treatment of mammals using antibodies to early pregnancy factor (epf)
DE69311796T2 (de) Peptide von dem caseinomacropeptid, antikorper dagegen und ihre andwendungen
KR890016165A (ko) 수도모나스 아에루기노사(Pseudomonas aeruginosa)에 대한 모노클로날 항체, 이의 제조방법 및 용도
FR2694938B1 (fr) Nouveaux peptides, anticorps diriges contre ces peptides, anticorps anti-idiotypiques, application a titre de medicaments, compositions pharmaceutiques et kits de diagnostic les renfermant.

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20151106